BIOLOGICAL WARFARE DEFENSE AGAINST ANTHRAX AND BOTULINUM

File: 120396_sep96_decls57_0008.txt
Page: 0008
Total Pages: 16

Subject: BIOLOGICAL WARFARE DEFENSE AGAINST ANTHRAX AND BOTULINUM        

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: INTERIM MEDICAL DOCTRINE BW DEFENSE AGAINST ANTHRAX                                             

Document Number:          1

Folder SEQ  #:          7









                                                          2


                                                AND
                                    mw.c@.r-Ltm, D     IS, AND
              2.1 IrldividUill, Collective, and ACtive @ter           ion - @ primary
              defensive                  BW agents are @vidual protection (chem3.cal
                      ve               ttle                   ) , C011@ve           on (N5:L
              for battalion a3.d staticrvdlvlslcn clearuq and the XM28 for           equipped
              hospitals); and act3.ve shelter protection. Active shelter          on
              @@ of @ing                 tents, GP tents, and ISO shelters bes@ other
              @ters from the @l& en%r               . Desext          at @y           ed
              that well @ed shelters usug field techniques (tape and sealuq shelter
              base with earth) afforded significant protection          vapor @
              penetration.          on factors of 60 for TEMPER tents, 20 for GP shelters,
              and greater than 60 for ISO shelters were

              2.2 vaccination - Will be given to St4 based upon          prioritizaticn.
              U.S. Pbrces will ccntirwa to be vaccinated as vaccine stocks are shi@ to
              the ACR. Medical laboratory            , hmlth care providers, and the NBC
                    tasked with the BW detection @icn shmld receive highest priority
              for anthrax and botulm= vaocimtlcn. These perscrml will poterrtially
              handle and         BW samples arid/or care for BW patients. @ Bw            M
              are riot      lam rior pose a bazard to other M. Medical persorml should
              exerc@ care in the              and handling of blood @les and other body
              fluids of         tic anthrax patients.

                   a. Anthrax

                       (1) @ anthrax va=ine (0.5 ml doses) is given at day 0, 14, and
ntervals. Fbr Operation
                     Shield the modified series is given at day 0 and 14. Sicjtuflcant
              levels of antibody and a         ve level against anthrax can be           two
                    after the se=nd vaccination.

                       (2) After all U.S. Fbrces have been vamimted with tw d@, each
              St4 will reoelve a      vaocimtlcn dose to                    on.

                  b. Botulimm          - Botulir&n vaocine (tcxoid)       d be given in 0.5
              ml       deep             ly at day 0, 14, and 84 (week 12) with p        ive
              levels of         es establ      two weeks foll      the        dose. Booster
              dose is given one year.

              2.3 Diagmsis

                  a. Antbrax

                       (1) Signs and           - Malaise, fatigue,      e pain, mild fever,
              ncrip     ve



                                                    2-1

Document 16 f:/Week-36/BX003203/INTERIM MEDICAL DOCTRINE BW DEFENSE AGAINST ANTHRAX/biological warfare defense against anthrax and b:11229616342415
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = INTERIM MEDICAL DOCTRINE BW DEFENSE AGAINST ANTHRAX
Folder Seq # = 7
Subject = BIOLOGICAL WARFARE DEFENSE AGAINST ANTHRAX AND B
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 22-NOV-1996